Simulations Plus

Driving Growth with Integrated Software, Services, and AI-Enabled Ecosystem

Conference call to be on Thursday, January 8, 2026, at 5 p.m. ET

Validated engines and AI-orchestrated ecosystem align with the emerging regulatory framework

Researchers found 70% of compounds designed in ADMET Predictor demonstrated significant activity during in vitro testing

Investment to accelerate innovations in biopharma development through Corporate Development Initiative

Updated full-year revenue guidance of between $76 to $80 million and adjusted diluted EPS of $0.93 to $1.06

Updates fiscal 2025 revenue guidance range

Third quarter fiscal 2025 full results to be released on July 2, 2025, with conference call at 5 p.m. ET

Updates fiscal 2025 revenue guidance range

Third quarter fiscal 2025 full results to be released on July 2, 2025, with conference call at 5 p.m. ET

Expanded functionality and advanced AI/ML capabilities deliver faster, more accurate predictions and streamline enterprise deployment

Newest version of the quantitative systems toxicology (QST) software supports drug-induced liver injury (DILI) prediction for pediatric patient populations

Modeling and simulation will be a key component for shift to non-animal methodologies

Introducing NAMVantage(TM), a flagship package offering PBPK and QSP professional services and regulatory strategy combined with built-in coaching and training

Total revenue grew 23% year-over-year driven by strong growth in both software and services

Simulations Plus will be participating in a fireside chat at the KeyBanc Capital Markets Virtual Healthcare Investor.

Industry partners to provide funding and data to support ACAT™ model improvements

SLP’s technology and expertise accelerates drug development and supports critical advancements in global healthcare

Total revenue up 31% year-over-year primarily driven by strong software growth

Funded collaboration will leverage current FDA partnership to include additional LAI technologies

Simulations Plus to Participate in the Stephens Annual Investment Conference

Collaboration goal to develop alternative methods to assess clinical performance of product variants under different conditions

Partnership will advance the field of ligand-based virtual screening to improve drug design and optimization activities